SwePub
Sök i LIBRIS databas

  Utökad sökning

L773:2509 4262 OR L773:2509 4254
 

Sökning: L773:2509 4262 OR L773:2509 4254 > Healthcare Cost Dev...

Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment : A Nationwide Observational Study 2006-2014

Nathanson, David (författare)
Karolinska Institutet
Sabale, Ugne (författare)
Astra Zeneca Nordic Baltic, Dept Hlth Econ, Astraallen B674, S-15185 Sodertalje, Sweden
Eriksson, Jan (författare)
Uppsala universitet,Klinisk diabetologi och metabolism
visa fler...
Nyström, Thomas (författare)
Karolinska Institutet
Norhammar, Anna (författare)
Karolinska Institutet
Olsson, Urban (författare)
Statisticon AB, Uppsala, Sweden
Bodegård, Johan (författare)
AstraZeneca Nordic Baltic, Med Dept, Oslo, Norway
visa färre...
 (creator_code:org_t)
2017-11-27
2018
Engelska.
Ingår i: PHARMACOECONOMICS-OPEN. - : SPRINGER INTERNATIONAL PUBLISHING AG. - 2509-4262 .- 2509-4254. ; 2:4, s. 393-402
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Objective: The objective of this study was to describe healthcare resource use and cost development in Sweden during 2006-2014 in a type 2 diabetes (T2D) population receiving glucose-lowering drugs (GLDs).Methods: In- and outpatient healthcare resource use and costs were extracted from mandatory national registries: the Cause of Death Register; the National Patient Register; and the Prescribed Drug Register. Primary care data were estimated based on an observational study including patients from 84 primary care centers in Sweden. Numbers of any cause inpatient, outpatient, and primary care contacts were extracted and direct healthcare costs were estimated.Results: During 2006-2014, the number of inpatient and primary care contacts increased by approximately 70% (from 45,559 to 78,245 and from 4.9 to 8.8 million, respectively) and outpatient care contacts almost doubled (from 105,653 to 209,417). Mean annual per patient costs increased by 13%, reaching (sic)4594. Total healthcare costs increased from (sic)835 million to (sic)1.684 billion. Inpatient care costs constituted 47% of total costs in 2014 ((sic)783 million), primary care accounted for 24% ((sic)405 million), outpatient care 18% ((sic)303 million), non-GLD medications 6% ((sic)109 million), and GLDs 5% ((sic)84 million). Cardiovascular diseases (CVDs) were the most costly disease group in inpatient care (26%), whereas managing unspecified factors influencing health and T2D-associated diseases were the most costly in outpatient care (16 and 11%, respectively).Conclusions: The healthcare costs of the GLD-treated T2D population doubled during 2006-2014, mostly driven by the increasing size of this population, of which inpatient care accounted for 47%. GLDs constituted the smallest share of costs. CVD was the most resource-requiring disease group.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Hälsovetenskap -- Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Health Sciences -- Health Care Service and Management, Health Policy and Services and Health Economy (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy